- Shares of Ocumetics Technology (TSXV:OTC) are up by almost 400 per cent following Monday’s announcement of a historical milestone: the first-in-human implant of a bionic intraocular lens
- Ocumetics is a Canadian research and product development company focused on vision-correction solutions
- Ocumetics stock has added 464.52 per cent year-over-year
Shares of Ocumetics Technology (TSXV:OTC) are up by almost 400 per cent following Monday’s announcement of a historical milestone: the first-in-human implant of a bionic intraocular lens.
This content has been prepared as part of a partnership with Ocumetics Technology Corp., and is intended for informational purposes only.
Unlike traditional monofocal or multifocal lenses, the Ocumetics Lens is designed to work with the natural movements of the eye, allowing the user to see clearly close up and at a distance without glasses or contacts following cataract surgery.
The successful procedure is an important step in the drive to restore dynamic vision, with initial post-operative results expected in the coming weeks and additional implants planned under the clinical trial program over the coming months.
Leadership insights
“This is a moment of immense pride for our team and everyone who has believed in Ocumetics from the beginning,” Dean Burns, Ocumetics Technology’s president and chief executive officer, stated in Monday’s news release. “For nearly two decades, we’ve been focused on a bold vision, one that many thought was out of reach. Our scientists, engineers, clinical advisors and partners have poured their hearts into this innovation. Today we celebrate this success, but we know the work is far from done. There are millions of people waiting for us to get the Ocumetics Lens to market, and we are more driven than ever to bring this solution to the world.”
“The Ocumetics accommodating intraocular lens has the potential to reshape the global standard of care first for cataract, and eventually, presbyopia patients,” Burns added. “This milestone reinforces Ocumetics’ position as a leader in the next generation of ophthalmic innovation. With aging populations around the globe demanding better vision solutions, the potential impact of the Ocumetics Lens is profound.”
About Ocumetics Technology
Ocumetics is a Canadian research and product development company focused on vision-correction solutions, including an intraocular lens that fits within the eye’s natural lens compartment.
Ocumetics stock (TSXV:OTC) is up by 75 per cent trading at C$1.75 as of 10:51 am ET. The stock has added 464.52 per cent year-over-year.
Join the discussion: Find out what investors are saying about this Canadian healthcare technology stock on the Ocumetics Technology Corp. Bullboard, and make sure to explore the rest of Stockhouse’s stock forums and message boards.
Stockhouse does not provide investment advice or recommendations. All investment decisions should be made based on your own research and consultation with a registered investment professional. The issuer is solely responsible for the accuracy of the information contained herein. For full disclaimer information, please click here.
